thiazoles has been researched along with masitinib in 101 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (6.93) | 29.6817 |
| 2010's | 72 (71.29) | 24.3611 |
| 2020's | 22 (21.78) | 2.80 |
| Authors | Studies |
|---|---|
| Bui, B; Italiano, A | 1 |
| Bader, T; Bellamy, F; Hermine, O; Moussy, A | 1 |
| Armand, JP; Bader, T; Blay, JY; Bui, BN; Hermine, O; Magné, N; Mansfield, CD; Massard, C; Moussy, A; Soria, JC | 1 |
| Bourgeois, P; Dubreuil, P; Flipo, RM; Gaudin, P; Gineste, P; Guy, L; Hermine, O; Le Loët, X; Mansfield, CD; Mariette, X; Moussy, A; Sibilia, J; Tebib, J | 1 |
| Aubier, M; Bader, T; Chanez, P; Charpin, D; de Blay, F; Garcia, G; Gineste, P; Hermine, O; Humbert, M; Leroyer, C; Magnan, A; Moussy, A; Pison, C; Prud'homme, A; Purohit, A; Tunon-de-Lara, JM; Vachier, I | 1 |
| Walker, UA | 1 |
| Arock, M; Auclair, C; Borge, L; Castéran, N; Ciufolini, M; Dubreuil, P; Gros, L; Hajem, B; Hermine, O; Humbert, M; Lermet, A; Letard, S; Leventhal, PS; Mansfield, CD; Moussy, A; Sippl, W; Voisset, E | 1 |
| Charpin, D; Granel, B; Hermine, O; Koeppel, MC; Rossi, P | 1 |
| Daigle, J; Hermine, O; Mansfield, CD; Moussy, A | 1 |
| Bader, T; Bertucci, F; Castéran, N; Dubreuil, P; Finetti, P; Hanssens, K; Hermine, O; Humbert, M; Iovanna, J; Letard, S; Mansfield, CD; Moussy, A | 1 |
| Adenis, A; Blay, JY; Bonvalot, S; Bouché, O; Bui, BN; Cioffi, A; Domont, J; Hermine, O; Kinet, JP; Lassau, N; Le Cesne, A; Moussy, A; Ray-Coquard, I | 1 |
| Deplanque, G; Hammel, P; Hermine, O; Kinet, JP; Levy, P; Mitry, E; Mornex, F; Moussy, A; Raymond, E; Rougier, P; Seitz, JF | 1 |
| Bonvalot, S; Cioffi, A; Dômont, J; Le Cesne, A; Tardieu, M | 1 |
| Atwater, SW; Carreras, JK; Dubreuil, P; Hahn, KA; Hermine, O; Kinet, JP; Ladue, T; Lana, SE; Legendre, AM; Moussy, A; Ogilvie, GK; Phillips, B; Prescott, DM; Rusk, A; Shaw, NG | 1 |
| Barete, S; Casassus, P; Dubreuil, P; Gineste, P; Grandpeix-Guyodo, C; Hermine, O; Lanternier, F; Lortholary, O; Mansfield, CD; Moussy, A; Palmérini, F; Paul, C; Sans, B; Suarez, F | 1 |
| Benatsou, B; Bidault, S; Blay, JY; Chami, L; Chebil, M; Cioffi, A; Koscielny, S; Lassau, N; Le Cesne, A; Massard, C | 1 |
| Morjaria, JB; Polosa, R; Proiti, M | 1 |
| Procoli, F | 1 |
| Dubreuil, P; Hermine, O; Humbert, M; Kow, K; Mansfield, CD; Moussy, A; Rose, B; Thamm, DH | 1 |
| Beco, L; Bensignor, E; Cadot, P; Campbell, K; Cannon, A; Dubreuil, P; Fontaine, J; Georgescu, G; Gogny-Goubert, M; Hadjaje, C; Hensel, P; Hermine, O; Jamet, JF; Marignac, G; Messinger, L; Moussy, A; Osborn, SC | 1 |
| Blay, JY; Chaigneau, L; Curtit, E; Dobi, E; Kalbacher, E; Mansi, L; Nguyen, T; Pivot, X; Viel, E | 1 |
| Aubourg, A; Chaigne, B; de Muret, A; Jonville-Bera, AP; Lagier, L; Machet, L; Samimi, M | 1 |
| Barete, S; Damaj, G; Georgin-Lavialle, S; Gineste, P; Hermine, O; Lortholary, O; Montestruc, F; Moura, DS; Moussy, A; Pillet, N; Sultan, S | 1 |
| Kim, EJ; Zalupski, MM | 1 |
| Dobbin, K; Dubreuil, P; Gogal, R; Hermine, O; Hurley, DJ; Lamberth, O; Lawrence, J; Saba, C; Turek, M; Vandenplas, ML | 1 |
| Aouba, A; Asnafi, V; Brouze, C; Canioni, D; Chandesris, MO; Dubreuil, P; Feger, F; Georgin-Lavialle, S; Gineste, P; Hanssens, K; Hermine, O; Lepelletier, Y; Letard, S; Lhermitte, L; Macintyre, E; Mansfield, CD; Moussy, A; Renand, A; Suarez, F; Yang, Y | 1 |
| Cohn, LA; DeClue, AE; Dodam, J; Guntur, V; Lee-Fowler, TM; Reinero, CR | 1 |
| Kow, K; Lyles, SE; Milner, RJ; Salute, ME | 1 |
| Benrabah, R; Clavelou, P; Dubreuil, P; Hermine, O; Moussy, A; Schmidt, N; Vermersch, P; Vongsouthi, C; Zéphir, H | 1 |
| Bondzio, A; Einspanier, R; Gruber, AD; Hummel, M; Klopfleisch, R; Lenze, D; Meyer, A; Schlieben, P; Weise, C | 1 |
| Airley, R | 1 |
| Argyle, DJ; Bavcar, S | 1 |
| Chapuis, T; Fink-Gremmels, J; Schrickx, JA; Teske, E; Zandvliet, M | 1 |
| Bacon, NJ; Fahey, CE; Kow, K; Milner, RJ; Salute, ME | 1 |
| Adam, K; D'allard, D; Descarpentries, C; Dubreuil, P; Floquet, C; Fontenay, M; Frisan, E; Gay, J; Kosmider, O; Lacombe, C; Mayeux, P; Verdier, F | 1 |
| Cornell, K; Feldhaeusser, BR; Gogal, RM; Lawrence, J; Turek, M | 1 |
| Essick, L; Legendre, AM; Rohrbach, BW; Smrkovski, OA | 1 |
| Avula, MN; Grainger, DW; McGill, LD; Rao, AN; Solzbacher, F | 1 |
| Orlowski, RZ | 1 |
| Gadaleta, C; Gadaleta, CD; Introna, M; Marech, I; Patruno, R; Ranieri, G; Zito, AF; Zizzo, N | 1 |
| Abuznait, AH; Anreddy, N; Ashby, CR; Chen, K; Chen, ZS; Kaddoumi, A; Kathawala, RJ; Patel, A; Sodani, K; Sun, YL | 1 |
| Feldhausser, B; Gogal, R; Hill, J; Lawrence, J; Saba, C; Turek, M; Vandenplas, ML | 1 |
| Ashby, CR; Chen, JJ; Chen, ZS; Kathawala, RJ; Patel, A; Talele, TT; Wang, DS; Wang, YJ; Zhang, YK | 1 |
| Alexander, M; Cekanova, M; Rathore, K | 1 |
| Acin, Y; Adenis, A; Bertucci, F; Blay, JY; Blésius, A; Bompas, E; Bouché, O; Bui-Nguyen, B; Bulusu, VR; Chaigneau, L; Domont, J; Dubreuil, P; Hermine, O; Isambert, N; Le Cesne, A; Mansfield, CD; Moussy, A; Ray-Coquard, I; Van Tine, BA | 1 |
| London, CA | 1 |
| Dobson, JM; Foale, RD; Miller, RL; Van Lelyveld, S; Warland, J | 1 |
| Dubreuil, P; Hermine, O; Kocic, I; Kowianski, P; Lietzau, G; Mansfield, C; Moussy, A; Rusiecka, I | 1 |
| Acin, Y; Atkins, J; Demarchi, M; Deplanque, G; Dubreuil, P; Flynn, P; Hammel, P; Hebbar, M; Hermine, O; Mansfield, CD; Melichar, B; Moussy, A; Moyé, L; Nowara, E; Piquemal, D; Ritter, D | 1 |
| Abad, S; Auladell, C; Beas-Zarate, C; Camins, A; Ettcheto, M; Folch, J; Lazarowski, A; Marin, M; Olloquequi, J; Pedrós, I; Petrov, D | 1 |
| Abdollahi, M; Nikfar, S; Safavi, M | 1 |
| Betz, D; Hirschberger, J; Holtermann, N; Kessler, M; Kiupel, M; Teske, E | 1 |
| Avula, M; Grainger, DW; Jones, D; McClain, D; McGill, LD; Rao, AN; Solzbacher, F | 1 |
| Camacho, J; Gamez, J; Salvado, M; Simon-Talero, M; Vargas, V; Vidal, M | 1 |
| Ammendola, M; De Sarro, G; Gadaleta, CD; Leporini, C; Marech, I; Oakley, C; Ranieri, G; Russo, E; Sacco, R; Sammarco, G | 1 |
| Agopian, J; Dubreuil, P; Grim, J; Hermine, O; Kolarova, R; Kopecky, J; Lukesova, S; Mansfield, C; Moussy, A; Navratilova, B; Papik, Z; Prosvicova, J | 1 |
| Abad, S; Auladell, C; Beas-Zarate, C; Camins, A; Ettcheto, M; Folch, J; García, ML; Olloquequi, J; Petrov, D; Sánchez-López, E | 1 |
| Im, JE; Jeong, JH; Kim, JT; Kim, JY; Kim, SR; Park, SG; Suh, W; Sung, JH; Woo, SJ | 1 |
| Grant, J; Lanore, D; North, S | 1 |
| Bracha, S; Goodall, CP; Helfand, SC; Löhr, CV; Marley, K; Milovancev, M | 1 |
| Babdor, J; Barbeito, L; Barreto-Núñez, R; Beckman, JS; Cassina, P; Díaz-Amarilla, P; Dubreuil, P; Gros, L; Guillo, M; Hermine, O; Ibarburu, S; Maciel, TT; Martínez-Palma, L; Moura, IC; Trias, E | 1 |
| Devine, L; Polzin, DJ | 1 |
| Bauer, K; Cerny-Reiterer, S; Hadzijusufovic, E; Hoermann, G; Pirker, A; Reifinger, M; Valent, P; Willmann, M | 1 |
| Dolgin, E | 1 |
| Afrin, LB; Agopian, J; Auclair, C; Barete, S; Bulai Livideanu, C; Canioni, D; Chandesris, MO; Damaj, G; Dubreuil, P; Fraitag, S; Frenzel, L; Gaillard, R; Georgin Lavialle, S; Grattan, C; Guillet, G; Hanssens, K; Hermine, O; Jassem, E; Kinet, JP; Lhermitte, L; Lortholary, O; Mansfield, C; Moussy, A; Niedoszytko, M; Paul, C; Verstovsek, S | 1 |
| Avallone, A; Botti, G; Capozzi, M; De Divitiis, C; De Stefano, A; Ottaiano, A; Tafuto, S | 1 |
| Beasley, G; Rossfeld, K; Salama, AK; Turner, MC; Tyler, D | 1 |
| Gómez-Fernández, C; Herranz-Pinto, P; Nieto-Rodríguez, D; Rueda-Carnero, JM | 1 |
| Scott, A | 1 |
| Barbeito, L; Barreto-Núñez, R; Beckman, JS; Dubreuil, P; Hermine, O; Ibarburu, S; Moura, IC; Trias, E; Varela, V | 1 |
| Audebert, S; Baudelet, E; Betzi, S; Casteran, N; Combes, S; De Sepulveda, P; Dubreuil, P; Gros, L; Hajem, B; Hammam, K; Humbert, M; Letard, S; Lopez, S; Lugari, A; Mansfield, C; Morelli, X; Moussy, A; Rebuffet, E; Saez-Ayala, M | 1 |
| Kiernan, MC | 1 |
| Belin, D; Belin-Rauscent, A; Everitt, BJ; Hermine, O; Lacoste, J; Moussy, A | 1 |
| Purvey, S; Saif, MW; Waheed, A | 1 |
| Bourn, J; Cekanova, M | 1 |
| Backman, JT; Filppula, AM; Mustonen, TM | 1 |
| Kim, HH; Korade, Z; Porter, NA; Wages, PA | 1 |
| Barbeito, L; Beckman, JS; Hermine, O; Ibarburu, S; King, PH; Kovacs, M; Kwon, Y; Moura, IC; Si, Y; Trias, E; Varela, V | 1 |
| Calabrò, C; Gadaleta, CD; Laforgia, M; Marech, I; Nardulli, P; Ranieri, G | 1 |
| van Den Berg, LH; van Eijk, RPA | 1 |
| Dobson, J; Giuliano, A | 1 |
| Cocorocchio, E; Conforti, F; Ferrucci, PF; Pala, L | 1 |
| Bonkobara, M; Dally, C; Gentilini, F; Kurita, S; Takanosu, M; Turba, ME | 1 |
| Abada, YS; Boucher, C; Cès, A; Delarasse, C; Delatour, B; Dhenain, M; Dubreuil, P; Fenaux, G; Forand, Y; Hermine, O; Legrand, A; Li, T; Martin, E; Nachiket, N; Youssef, I | 1 |
| Chen, JJ | 1 |
| El-Maghraby, WH; El-Malla, SF; Mabrouk, MM | 1 |
| Helm, J; Kuijlaars, M; McBrearty, A | 1 |
| Aguayo-Ortiz, R; Figueroa-Figueroa, DI; Hernández-Luis, F; Martínez-Ortega, U | 1 |
| Azizi, SA; Baker, SC; Botten, JW; Brooke, CB; Bruce, EA; Chen, S; DeMarco, JK; Dickinson, BC; Drayman, N; Dvorkin, S; Firpo, MR; Froggatt, HM; Furlong, K; Han, KY; Heaton, NS; Jedrzejczak, R; Joachimiak, A; Jones, KA; Kathayat, RS; Lee, H; Maltseva, NI; Mastrodomenico, V; Meyer, B; Missiakas, D; Mounce, BC; Muñoz-Alía, MÁ; Nair, V; Nicolaescu, V; O'Brien, A; Palmer, KE; Randall, G; Schmidt, MM; Schuster, B; Severson, WE; Tan, K; Tay, S; Tomatsidou, A; Vignuzzi, M | 1 |
| Alamón, C; Barbeito, L; Hermine, O; Ibarburu, S; King, PH; Kovacs, M; Kwon, Y; Maciel, C; Si, Y; Tarragó, L; Trias, E; Varela, V | 1 |
| Auladell, C; Camins, A; Cano, A; Ettcheto, M; Folch, J; Sanchez-López, E; Verdaguer, E | 1 |
| Collins-Praino, LE; Corrigan, F; Guglietti, B; Mustafa, S; Sivasankar, S | 1 |
| Demir-Dora, D; Goksu Erol, AY; Kocanci, FG; Uysal, H | 1 |
| Brieva-Ruiz, L; Fox, RJ; Hermine, O; Maciejowski, M; Mansfield, C; Moussy, A; Paul, F; Ramio-Torrenta, L; Schwab, M; Vermersch, P | 1 |
| Granados-Soler, JL; Hewicker-Trautwein, M; Klose, K; Murua Escobar, H; Nolte, I; Packeiser, EM | 1 |
| Nagahara, Y; Semba, Y; Shinomiya, T; Takahashi, S; Yamamoto, S | 1 |
| Ancidoni, A; Carbone, E; Corbo, M; Crestini, A; Lacorte, E; Lo Giudice, M; Piscopo, P; Rivabene, R; Vanacore, N | 1 |
| Crouch, RD; Jackson, KD; Latham, BD; Oskin, DS; Vergne, MJ | 1 |
| Bertrand, J; Ciarimboli, G; Haag, J; Harrach, S; Neugebauer, U; Schröter, R; Steinbüchel, M | 1 |
| Doskas, T; Dubois, B; Hermine, O; Lipschitz, S; López-Arrieta, J; Mansfield, CD; Moroz, S; Moussy, A; Spiru, L; Tsolaki, M; Venger, O; Vermersch, P | 1 |
| Durojaye, OA; Nwanguma, BC; Odiba, AS; Okoro, NO | 1 |
18 review(s) available for thiazoles and masitinib
| Article | Year |
|---|---|
[Gastrointestinal stromal tumors: molecular aspects and therapeutic implications].
Topics: Antineoplastic Agents; Benzamides; Benzenesulfonates; Disease Progression; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Mutation; Neoplasm Proteins; Niacinamide; Oligonucleotides; Phenylurea Compounds; Phthalazines; Piperazines; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyridines; Pyrimidines; Pyrroles; Receptor, Platelet-Derived Growth Factor alpha; Sorafenib; Staurosporine; Sunitinib; Thiazoles | 2008 |
[Focus on GIST management].
Topics: Antineoplastic Agents; Benzamides; Benzenesulfonates; Chemotherapy, Adjuvant; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Niacinamide; Phenylurea Compounds; Piperazines; Piperidines; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Pyrroles; Sorafenib; Sunitinib; Thiazoles | 2010 |
Stratified medicine in selecting biologics for the treatment of severe asthma.
Topics: Antibodies, Anti-Idiotypic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Asthma; Benzamides; Biological Products; Daclizumab; Humans; Immunoglobulin G; Omalizumab; Piperidines; Pyridines; Receptors, Interleukin-4; Thiazoles; Treatment Outcome; Tumor Necrosis Factor-alpha | 2011 |
Systemic therapy for advanced gastrointestinal stromal tumors: beyond imatinib.
Topics: Antineoplastic Agents; Benzamides; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Mutation; Piperazines; Piperidines; Proto-Oncogene Proteins c-kit; Pyridines; Pyrimidines; Pyrroles; Receptors, Platelet-Derived Growth Factor; Sunitinib; Thiazoles | 2011 |
Receptor tyrosine kinase inhibitors: molecularly targeted drugs for veterinary cancer therapy.
Topics: Animals; Antineoplastic Agents; Benzamides; Drug Therapy, Combination; Humans; Indoles; Neoplasms; Piperidines; Pyridines; Pyrroles; Receptor Protein-Tyrosine Kinases; Thiazoles | 2012 |
Novel agents for multiple myeloma to overcome resistance in phase III clinical trials.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzamides; Clinical Trials, Phase III as Topic; Disease-Free Survival; Drug Resistance, Neoplasm; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Immunologic Factors; Indoles; Multiple Myeloma; Oligopeptides; Panobinostat; Phosphorylcholine; Piperidines; Proteasome Inhibitors; Pyridines; Remission Induction; Thalidomide; Thiazoles; Treatment Outcome; Vorinostat | 2013 |
Masitinib (AB1010), from canine tumor model to human clinical development: where we are?
Topics: Animals; Benzamides; Dogs; Humans; Neoplasms, Experimental; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Mas; Pyridines; Structure-Activity Relationship; Thiazoles | 2014 |
Small molecule inhibitors in veterinary oncology practice.
Topics: Animals; Benzamides; Cat Diseases; Cats; Dog Diseases; Dogs; Indoles; Neoplasms; Piperidines; Protein Kinase Inhibitors; Pyridines; Pyrroles; Thiazoles | 2014 |
Masitinib for the treatment of mild to moderate Alzheimer's disease.
Topics: Alzheimer Disease; Animals; Benzamides; Humans; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyridines; Thiazoles | 2015 |
A systematic review of drugs in late-stage development for the treatment of multiple sclerosis: a focus on oral synthetic drugs.
Topics: Benzamides; Humans; Immunologic Factors; Multiple Sclerosis; Piperidines; Pyridines; Quinolones; Small Molecule Libraries; Thiazoles | 2015 |
Targeting mast cells in gastric cancer with special reference to bone metastases.
Topics: Animals; Antigens, CD34; Benzamides; Benzamidines; Bone and Bones; Bone Neoplasms; Bone Resorption; Disease Progression; Gabexate; Guanidines; Humans; Imatinib Mesylate; Immune System; Mast Cells; Neovascularization, Pathologic; NF-kappa B; Piperidines; Proto-Oncogene Proteins c-kit; Pyridines; Stomach Neoplasms; Thiazoles; Tryptases | 2015 |
Current Research Therapeutic Strategies for Alzheimer's Disease Treatment.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Benzamides; Benzodioxoles; Brain; Disease Models, Animal; Humans; Mice; Neurons; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-fyn; PrPC Proteins; Pyridines; Quinazolines; Receptor, Metabotropic Glutamate 5; Receptors, N-Methyl-D-Aspartate; Receptors, Serotonin; Synapses; Thiazoles | 2016 |
Gemcitabine mono-therapy versus gemcitabine plus targeted therapy in advanced pancreatic cancer: a meta-analysis of randomized phase III trials.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Clinical Trials, Phase III as Topic; Deoxycytidine; Disease Progression; Gemcitabine; Humans; Molecular Targeted Therapy; Pancreatic Neoplasms; Piperidines; Pyridines; Randomized Controlled Trials as Topic; Survival Analysis; Thiazoles | 2017 |
Can binimetinib, encorafenib and masitinib be more efficacious than currently available mutation-based targeted therapies for melanoma treatment?
Topics: Benzamides; Benzimidazoles; Carbamates; Humans; Melanoma; Mutation; Piperidines; Protein Kinase Inhibitors; Proteomics; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-kit; Pyridines; Skin Neoplasms; Sulfonamides; Thiazoles | 2017 |
An evaluation of masitinib for treating systemic mastocytosis.
Topics: Benzamides; Humans; Imatinib Mesylate; Mast Cells; Mastocytosis, Systemic; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyridines; Thiazoles | 2019 |
Masitinib for the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Benzamides; Cognition; Humans; Piperidines; Protein Kinase Inhibitors; Pyridines; Thiazoles | 2021 |
Fyn Kinase Activity and Its Role in Neurodegenerative Disease Pathology: a Potential Universal Target?
Topics: Alzheimer Disease; Amyloid beta-Peptides; Benzamides; Central Nervous System; Dasatinib; Humans; Molecular Targeted Therapy; Multiple Sclerosis; Myelin Sheath; Nerve Tissue Proteins; Neurodegenerative Diseases; Oligodendroglia; Parkinson Disease; Piperidines; Proto-Oncogene Proteins c-fyn; PrPC Proteins; Pyridines; Receptors, N-Methyl-D-Aspartate; T-Cell Antigen Receptor Specificity; T-Lymphocyte Subsets; tau Proteins; Thiazoles | 2021 |
A systematic review on drugs for synaptic plasticity in the treatment of dementia.
Topics: Alzheimer Disease; Benzamides; Bryostatins; Humans; Levetiracetam; Neuronal Plasticity; Piperidines; Pyridines; Thiazoles | 2022 |
16 trial(s) available for thiazoles and masitinib
| Article | Year |
|---|---|
Phase 1 dose-escalation study of oral tyrosine kinase inhibitor masitinib in advanced and/or metastatic solid cancers.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Benzamides; Dose-Response Relationship, Drug; Female; Gastrointestinal Stromal Tumors; Humans; Male; Maximum Tolerated Dose; Middle Aged; Piperidines; Pyridines; Receptor Protein-Tyrosine Kinases; Thiazoles; Treatment Outcome | 2009 |
Masitinib in the treatment of active rheumatoid arthritis: results of a multicentre, open-label, dose-ranging, phase 2a study.
Topics: Adult; Aged; Arthritis, Rheumatoid; Benzamides; Dose-Response Relationship, Drug; Exanthema; Female; Humans; Male; Middle Aged; Piperidines; Prospective Studies; Pyridines; Thiazoles; Treatment Outcome | 2009 |
Masitinib, a c-kit/PDGF receptor tyrosine kinase inhibitor, improves disease control in severe corticosteroid-dependent asthmatics.
Topics: Administration, Oral; Adolescent; Adult; Aged; Anti-Asthmatic Agents; Asthma; Benzamides; Edema; Exanthema; Female; France; Humans; Hydroxycorticosteroids; Male; Medication Adherence; Middle Aged; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyridines; Receptors, Platelet-Derived Growth Factor; Thiazoles; Treatment Outcome | 2009 |
Phase II study of oral masitinib mesilate in imatinib-naïve patients with locally advanced or metastatic gastro-intestinal stromal tumour (GIST).
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Disease-Free Survival; Dose-Response Relationship, Drug; Female; France; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Piperazines; Piperidines; Proto-Oncogene Proteins c-kit; Pyridines; Pyrimidines; Thiazoles; Treatment Outcome | 2010 |
Safety and activity of masitinib in combination with gemcitabine in patients with advanced pancreatic cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Deoxycytidine; Disease Progression; Dose-Response Relationship, Drug; Endpoint Determination; Female; Gemcitabine; Hematologic Diseases; Humans; Male; Middle Aged; Pancreatic Neoplasms; Piperidines; Pyridines; Survival Analysis; Thiazoles | 2010 |
Masitinib for the treatment of systemic and cutaneous mastocytosis with handicap: a phase 2a study.
Topics: Adult; Benzamides; Dose-Response Relationship, Drug; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Male; Mastocytosis, Cutaneous; Mastocytosis, Systemic; Middle Aged; Mutation, Missense; Piperidines; Pyridines; Thiazoles; Treatment Outcome | 2010 |
Quantitative functional imaging by dynamic contrast enhanced ultrasonography (DCE-US) in GIST patients treated with masatinib.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Blood Volume; Contrast Media; Female; Fluorodeoxyglucose F18; France; Gastrointestinal Stromal Tumors; Humans; Male; Middle Aged; Molecular Targeted Therapy; Perfusion Imaging; Phospholipids; Piperidines; Positron-Emission Tomography; Predictive Value of Tests; Prospective Studies; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyridines; Radiopharmaceuticals; Receptor, Fibroblast Growth Factor, Type 3; Receptors, Platelet-Derived Growth Factor; Sulfur Hexafluoride; Thiazoles; Time Factors; Tomography, X-Ray Computed; Treatment Outcome; Ultrasonography | 2012 |
Masitinib decreases signs of canine atopic dermatitis: a multicentre, randomized, double-blind, placebo-controlled phase 3 trial.
Topics: Animals; Benzamides; Dermatitis, Atopic; Dog Diseases; Dogs; Double-Blind Method; Drug Administration Schedule; Female; Male; Piperidines; Prospective Studies; Protein Kinase Inhibitors; Pyridines; Severity of Illness Index; Thiazoles; Treatment Outcome | 2011 |
Depression in patients with mastocytosis: prevalence, features and effects of masitinib therapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Depression; Female; Humans; Male; Mastocytosis; Middle Aged; Piperidines; Pyridines; Thiazoles; Young Adult | 2011 |
Masitinib treatment in patients with progressive multiple sclerosis: a randomized pilot study.
Topics: Administration, Oral; Benzamides; Female; France; Humans; Male; Middle Aged; Multiple Sclerosis; Pilot Projects; Piperidines; Placebo Effect; Pyridines; Thiazoles; Treatment Outcome | 2012 |
Masitinib in advanced gastrointestinal stromal tumor (GIST) after failure of imatinib: a randomized controlled open-label trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Disease-Free Survival; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Male; Middle Aged; Piperazines; Piperidines; Prospective Studies; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyridines; Pyrimidines; Pyrroles; Sunitinib; Thiazoles; Treatment Failure | 2014 |
A randomized, placebo-controlled phase III trial of masitinib plus gemcitabine in the treatment of advanced pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Biomarkers, Tumor; Carcinoma, Pancreatic Ductal; Deoxycytidine; Europe; Female; Gemcitabine; Humans; Intention to Treat Analysis; Male; Middle Aged; Oxidoreductases; Pancreatic Neoplasms; Pharmacogenetics; Piperidines; Precision Medicine; Predictive Value of Tests; Proportional Hazards Models; Prospective Studies; Protein Kinase Inhibitors; Pyridines; Risk Factors; Thiazoles; Time Factors; Treatment Outcome; United States | 2015 |
Masitinib monotherapy in canine epitheliotropic lymphoma.
Topics: Animals; Becaplermin; Benzamides; Dog Diseases; Dogs; Immunohistochemistry; Lymphoma, T-Cell; Piperidines; Platelet-Derived Growth Factor; Proto-Oncogene Proteins c-kit; Proto-Oncogene Proteins c-sis; Pyridines; Receptor, Platelet-Derived Growth Factor alpha; Receptor, Platelet-Derived Growth Factor beta; Remission Induction; Thiazoles; Treatment Outcome | 2016 |
Masitinib for treatment of severely symptomatic indolent systemic mastocytosis: a randomised, placebo-controlled, phase 3 study.
Topics: Adult; Aged; Aged, 80 and over; Asthenia; Benzamides; Diarrhea; Double-Blind Method; Exanthema; Female; Humans; Male; Mastocytosis, Systemic; Middle Aged; Piperidines; Protein Kinase Inhibitors; Pyridines; Severity of Illness Index; Thiazoles; Treatment Outcome; Urticaria; Young Adult | 2017 |
Efficacy and Safety of Masitinib in Progressive Forms of Multiple Sclerosis: A Randomized, Phase 3, Clinical Trial.
Topics: Adolescent; Adult; Benzamides; Disease Progression; Double-Blind Method; Female; Humans; Male; Middle Aged; Multiple Sclerosis, Chronic Progressive; Outcome Assessment, Health Care; Piperidines; Protein Kinase Inhibitors; Pyridines; Thiazoles; Young Adult | 2022 |
Masitinib for mild-to-moderate Alzheimer's disease: results from a randomized, placebo-controlled, phase 3, clinical trial.
Topics: Activities of Daily Living; Alzheimer Disease; Humans; Memantine; Thiazoles | 2023 |
67 other study(ies) available for thiazoles and masitinib
| Article | Year |
|---|---|
Pharmacokinetics of masitinib in cats.
Topics: Animals; Benzamides; Biological Availability; Cats; Dogs; Female; Injections, Intravenous; Male; Mast Cells; Piperidines; Proto-Oncogene Proteins c-kit; Pyridines; Rats; Thiazoles | 2009 |
More about masitinib.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Benzamides; Clinical Trials, Phase II as Topic; Humans; Piperidines; Pyridines; Thiazoles | 2009 |
Masitinib (AB1010), a potent and selective tyrosine kinase inhibitor targeting KIT.
Topics: Animals; Benzamides; Bone Marrow Cells; Drug Evaluation, Preclinical; Female; Humans; Inhibitory Concentration 50; Mice; Mice, Nude; Models, Molecular; Mutation; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyridines; Recombinant Proteins; Thiazoles | 2009 |
Churg and Strauss vasculitis in the course of masitinib treatment: a first report.
Topics: Asthma; Benzamides; Churg-Strauss Syndrome; Humans; Male; Middle Aged; Piperidines; Protein-Tyrosine Kinases; Pyridines; Thiazoles; Treatment Outcome | 2010 |
Masitinib for the treatment of canine atopic dermatitis: a pilot study.
Topics: Animals; Benzamides; Dermatitis, Atopic; Dog Diseases; Dogs; Drug-Related Side Effects and Adverse Reactions; Pilot Projects; Piperidines; Pruritus; Pyridines; Severity of Illness Index; Skin; Thiazoles; Treatment Outcome | 2010 |
Masitinib combined with standard gemcitabine chemotherapy: in vitro and in vivo studies in human pancreatic tumour cell lines and ectopic mouse model.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Disease Models, Animal; Gemcitabine; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Inhibitory Concentration 50; Male; Mice; Mice, SCID; Pancreatic Neoplasms; Piperidines; Pyridines; Thiazoles | 2010 |
Evaluation of 12- and 24-month survival rates after treatment with masitinib in dogs with nonresectable mast cell tumors.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Benzamides; Dog Diseases; Dogs; Mast-Cell Sarcoma; Neoplasm Staging; Patient Selection; Piperidines; Predictive Value of Tests; Pyridines; Survival Rate; Survivors; Thiazoles; Time Factors | 2010 |
Clinical trial on the efficacy of masitinib in canine IBD.
Topics: Animals; Anti-Inflammatory Agents; Benzamides; Clinical Trials as Topic; Dog Diseases; Dogs; Inflammatory Bowel Diseases; Piperidines; Pyridines; Thiazoles; Treatment Outcome | 2010 |
Masitinib as a chemosensitizer of canine tumor cell lines: a proof of concept study.
Topics: Animals; Antineoplastic Agents; Benzamides; Cell Line, Tumor; Deoxycytidine; Dog Diseases; Dogs; Doxorubicin; Drug Synergism; Gemcitabine; Inhibitory Concentration 50; Piperidines; Protein Kinase Inhibitors; Pyridines; Sarcoma; Thiazoles; Vinblastine | 2012 |
[KIT and KIT: from biology to clinical use].
Topics: Antineoplastic Agents; Benzamides; Benzenesulfonates; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Niacinamide; Phenylurea Compounds; Piperazines; Piperidines; Prognosis; Protein Kinase Inhibitors; Proto-Oncogene Mas; Proto-Oncogene Proteins c-kit; Pyridines; Pyrimidines; Pyrroles; Sorafenib; Sunitinib; Thiazoles | 2012 |
Stevens-Johnson Syndrome induced by masitinib.
Topics: Adenocarcinoma; Benzamides; Colonic Neoplasms; Drug Eruptions; Humans; Male; Middle Aged; Piperidines; Protein Kinase Inhibitors; Pyridines; Stevens-Johnson Syndrome; Thiazoles | 2012 |
Masitinib demonstrates anti-proliferative and pro-apoptotic activity in primary and metastatic feline injection-site sarcoma cells.
Topics: Animals; Antineoplastic Agents; Benzamides; Cat Diseases; Cats; Cell Line, Tumor; Dose-Response Relationship, Drug; Flow Cytometry; Gene Expression Regulation, Neoplastic; Piperidines; Platelet-Derived Growth Factor; Pyridines; Receptors, Platelet-Derived Growth Factor; Sarcoma; Soft Tissue Neoplasms; Thiazoles; Vaccines, Inactivated | 2012 |
Mast cell leukemia: identification of a new c-Kit mutation, dup(501-502), and response to masitinib, a c-Kit tyrosine kinase inhibitor.
Topics: Aged; Animals; Antineoplastic Agents; Base Sequence; Benzamides; Chlorocebus aethiops; COS Cells; Female; Humans; Immunophenotyping; Leukemia, Mast-Cell; Mast Cells; Mutation; Neoplastic Cells, Circulating; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyridines; Thiazoles; Tryptases | 2012 |
The tyrosine kinase inhibitor masitinib blunts airway inflammation and improves associated lung mechanics in a feline model of chronic allergic asthma.
Topics: Allergens; Animals; Anti-Asthmatic Agents; Asthma; Benzamides; Bronchoalveolar Lavage Fluid; Cats; Chronic Disease; Cynodon; Eosinophils; Immunoglobulin E; Inflammation; Lung; Male; Methacholine Chloride; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Thiazoles | 2012 |
In vitro effects of the tyrosine kinase inhibitor, masitinib mesylate, on canine hemangiosarcoma cell lines.
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzamides; Caspase 3; Caspase 7; Cell Line, Tumor; Cell Survival; Dogs; Dose-Response Relationship, Drug; Hemangiosarcoma; In Situ Nick-End Labeling; In Vitro Techniques; Neoplasms, Vascular Tissue; Piperidines; Protein-Tyrosine Kinases; Pyridines; Skin Neoplasms; Thiazoles; Vascular Endothelial Growth Factor A | 2012 |
Transcriptome and proteome analysis of tyrosine kinase inhibitor treated canine mast cell tumour cells identifies potentially kit signaling-dependent genes.
Topics: Animals; Benzamides; Cell Death; Cell Line, Tumor; Cell Proliferation; Dogs; Gene Expression Regulation, Neoplastic; Mastocytoma; Piperidines; Proto-Oncogene Proteins c-kit; Pyridines; RNA, Messenger; Signal Transduction; Thiazoles; Transcriptome; Up-Regulation | 2012 |
Lab reports and cat scans: can veterinary oncology guide our way to new treatments for human cancers?
Topics: Animals; Antineoplastic Agents; Benzamides; Breast Neoplasms; Cats; Disease Models, Animal; Dogs; Female; Humans; Imatinib Mesylate; Indoles; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mast-Cell Sarcoma; Neoplasms; Piperazines; Piperidines; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Pyrroles; Thiazoles; Transcriptome | 2012 |
Masitinib reverses doxorubicin resistance in canine lymphoid cells by inhibiting the function of P-glycoprotein.
Topics: Animals; Antibiotics, Antineoplastic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Benzamides; Cell Line, Tumor; Dogs; Dose-Response Relationship, Drug; Doxorubicin; Drug Resistance, Neoplasm; Fluoresceins; Gene Expression Regulation; Piperidines; Protein Kinase Inhibitors; Pyridines; Rhodamine 123; Succinimides; Thiazoles | 2013 |
Apoptotic effects of the tyrosine kinase inhibitor, masitinib mesylate, on canine osteosarcoma cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzamides; Bone Neoplasms; Cell Line, Tumor; Cell Survival; Dogs; Dose-Response Relationship, Drug; Osteosarcoma; Piperidines; Protein Kinase Inhibitors; Pyridines; Thiazoles; Vascular Endothelial Growth Factor A | 2013 |
Tyrosine kinase inhibitors induce down-regulation of c-Kit by targeting the ATP pocket.
Topics: Adenosine Triphosphate; Benzamides; Binding Sites; Cell Line; Down-Regulation; Erythroblasts; Humans; Imatinib Mesylate; Ligands; Lysosomes; Piperazines; Piperidines; Protein Kinase Inhibitors; Protein Transport; Protein-Tyrosine Kinases; Proteolysis; Proto-Oncogene Proteins c-kit; Pyridines; Pyrimidines; Thiazoles | 2013 |
Influence of different cell storage/culture conditions on spontaneous proliferation and level of tyrosine kinase receptor inhibition in two feline injection-site sarcoma cell lines.
Topics: Animals; Apoptosis; Benzamides; Cats; Cell Culture Techniques; Cell Line, Tumor; Cell Proliferation; Cell Survival; Piperidines; Preservation, Biological; Protein Kinase Inhibitors; Pyridines; Sarcoma; Thiazoles | 2013 |
Masitinib mesylate for metastatic and non-resectable canine cutaneous mast cell tumours.
Topics: Animals; Benzamides; Disease-Free Survival; Dog Diseases; Dogs; Female; Kaplan-Meier Estimate; Male; Mastocytosis, Cutaneous; Neoplasm Staging; Piperidines; Protein Kinase Inhibitors; Pyridines; Schools, Veterinary; Skin Neoplasms; Tennessee; Thiazoles | 2015 |
Modulation of the foreign body response to implanted sensor models through device-based delivery of the tyrosine kinase inhibitor, masitinib.
Topics: Animals; Benzamides; Biocompatible Materials; Biosensing Techniques; Foreign-Body Reaction; Lactic Acid; Male; Mice; Mice, Inbred C57BL; Piperidines; Polyethylene Glycols; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Prostheses and Implants; Protein Kinase Inhibitors; Pyridines; Thiazoles | 2013 |
Masitinib antagonizes ATP-binding cassette subfamily C member 10-mediated paclitaxel resistance: a preclinical study.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cell Line, Tumor; Drug Resistance, Multiple; Drug Resistance, Neoplasm; HEK293 Cells; Humans; Mice; Multidrug Resistance-Associated Proteins; Paclitaxel; Piperidines; Pyridines; Thiazoles | 2014 |
Masitinib mesylate does not enhance sensitivity to radiation in three feline injection-site sarcoma cell lines under normal growth conditions.
Topics: Animals; Benzamides; Cat Diseases; Cats; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Piperidines; Protein Kinase Inhibitors; Pyridines; Radiation-Sensitizing Agents; Sarcoma; Thiazoles | 2014 |
Masitinib antagonizes ATP-binding cassette subfamily G member 2-mediated multidrug resistance.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Benzamides; Cell Line, Tumor; Drug Resistance, Multiple; Drug Synergism; HEK293 Cells; Humans; Mitoxantrone; Models, Molecular; Molecular Docking Simulation; Neoplasm Proteins; Piperidines; Protein Kinase Inhibitors; Pyridines; Thiazoles | 2014 |
Piroxicam inhibits Masitinib-induced cyclooxygenase 2 expression in oral squamous cell carcinoma cells in vitro.
Topics: Animals; Benzamides; Carcinoma, Squamous Cell; Cats; Cell Line, Tumor; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Dogs; Gene Expression Regulation, Enzymologic; Humans; Mouth Neoplasms; Piperidines; Piroxicam; Protein Kinase Inhibitors; Pyridines; Thiazoles | 2014 |
A retrospective review of treatment and response of high-risk mast cell tumours in dogs.
Topics: Animals; Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Dog Diseases; Dogs; Mastocytoma; Neoplasm Grading; Piperidines; Protein Kinase Inhibitors; Pyridines; Retrospective Studies; Risk Factors; Survival Analysis; Thiazoles; Treatment Outcome | 2016 |
Neuroprotective effect of masitinib in rats with postischemic stroke.
Topics: Animals; Behavior, Animal; Benzamides; Brain; Brain Ischemia; Drug Synergism; Drug Therapy, Combination; Hypnotics and Sedatives; Male; Neuroprotective Agents; Piperidines; Pyridines; Rats, Wistar; Stroke; Thiazoles; Tissue Plasminogen Activator | 2015 |
Local release of masitinib alters in vivo implantable continuous glucose sensor performance.
Topics: Animals; Benzamides; Biosensing Techniques; Blood Glucose; Blood Glucose Self-Monitoring; Drug Implants; Equipment Design; Equipment Failure Analysis; Male; Mice; Mice, Inbred C57BL; Piperidines; Prostheses and Implants; Pyridines; Reproducibility of Results; Sensitivity and Specificity; Thiazoles | 2016 |
Autoimmune-like hepatitis during masitinib therapy in an amyotrophic lateral sclerosis patient.
Topics: Adult; Amyotrophic Lateral Sclerosis; Azathioprine; Benzamides; Biopsy; Chemical and Drug Induced Liver Injury; Drug Therapy, Combination; Female; Hepatitis, Autoimmune; Humans; Immunosuppressive Agents; Piperidines; Prednisone; Protein Kinase Inhibitors; Pyridines; Randomized Controlled Trials as Topic; Severity of Illness Index; Thiazoles; Time Factors; Treatment Outcome | 2015 |
Rapid and clinically significant response to masitinib in the treatment of mucosal primary esophageal melanoma with somatic KIT exon 11 mutation involving brain metastases: A case report.
Topics: Benzamides; Brain Neoplasms; Esophageal Neoplasms; Exons; Fatal Outcome; Humans; Male; Melanoma; Middle Aged; Mutation; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyridines; Thiazoles | 2015 |
The cKit Inhibitor, Masitinib, Prevents Diabetes-Induced Retinal Vascular Leakage.
Topics: Animals; Benzamides; Blood-Retinal Barrier; Blotting, Western; Capillary Permeability; Cells, Cultured; Diabetes Mellitus, Experimental; Diabetic Retinopathy; Endothelium, Vascular; Gene Expression Regulation; Humans; Immunohistochemistry; Intravitreal Injections; Male; Mice; Mice, Inbred C57BL; Piperidines; Protein Kinase Inhibitors; Pyridines; Rats; Rats, Sprague-Dawley; Retinal Diseases; Retinal Vessels; Reverse Transcriptase Polymerase Chain Reaction; RNA; Signal Transduction; Stem Cell Factor; Thiazoles; Vascular Resistance | 2016 |
Clinical response of masitinib mesylate in the treatment of canine macroscopic mast cell tumours.
Topics: Animals; Antineoplastic Agents; Benzamides; Dog Diseases; Dogs; Female; Male; Mast Cells; Neoplasms, Connective Tissue; Piperidines; Pyridines; Retrospective Studies; Survival Rate; Thiazoles | 2016 |
Antiproliferative effects of masitinib and imatinib against canine oral fibrosarcoma in vitro.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cell Line, Tumor; Cell Proliferation; Dog Diseases; Dogs; Doxorubicin; Fibrosarcoma; Imatinib Mesylate; Mouth Neoplasms; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyridines; Receptor, Platelet-Derived Growth Factor alpha; Receptor, Platelet-Derived Growth Factor beta; Thiazoles; Vascular Endothelial Growth Factor Receptor-2 | 2016 |
Post-paralysis tyrosine kinase inhibition with masitinib abrogates neuroinflammation and slows disease progression in inherited amyotrophic lateral sclerosis.
Topics: Amyotrophic Lateral Sclerosis; Animals; Benzamides; Cell Death; Disease Models, Animal; Disease Progression; Encephalitis; Humans; Male; Motor Neurons; Mutation; Neuroglia; Paralysis; Piperidines; Protein Kinase Inhibitors; Pyridines; Rats; Rats, Transgenic; Spinal Cord; Superoxide Dismutase; Thiazoles | 2016 |
Presumed masitinib-induced nephrotic syndrome and azotemia in a dog.
Topics: Animals; Antineoplastic Agents; Azotemia; Benzamides; Dog Diseases; Dogs; Female; Mastocytoma; Nephrotic Syndrome; Piperidines; Protein-Tyrosine Kinases; Pyridines; Thiazoles | 2016 |
IL-4 downregulates expression of the target receptor CD30 in neoplastic canine mast cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzamides; Brentuximab Vedotin; Cell Line, Tumor; Cytokines; Dog Diseases; Dogs; Down-Regulation; Drug Synergism; Female; Immunoconjugates; Interleukin-4; Ki-1 Antigen; Male; Mastocytosis; Piperidines; Pyridines; Staurosporine; Thiazoles | 2017 |
Therapies: Progressive steps.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antigens, CD20; Azetidines; B-Lymphocytes; Benzamides; Benzyl Compounds; Blood-Brain Barrier; Clinical Trials as Topic; Disease Progression; Dogs; Drug Approval; Fingolimod Hydrochloride; Hope; Humans; Male; Mice; Multiple Sclerosis, Chronic Progressive; Neuroprotective Agents; Piperidines; Precision Medicine; Pyridines; Rituximab; Thiazoles; Ubiquinone; United States; United States Food and Drug Administration | 2016 |
Subacute cutaneous lupus erythematosus induced by masitinib.
Topics: Aged; Antineoplastic Agents; Benzamides; Drug Eruptions; Female; Humans; Lupus Erythematosus, Cutaneous; Piperidines; Protein Kinase Inhibitors; Pyridines; Thiazoles | 2017 |
Drug therapy: On the treatment trail for ALS.
Topics: Amyotrophic Lateral Sclerosis; Antipyrine; Benzamides; C9orf72 Protein; Clinical Trials as Topic; Disease Progression; Drug Therapy, Combination; Edaravone; Genetic Therapy; Humans; Imidazoles; Mesenchymal Stem Cells; Motor Neurons; Neuroglia; Off-Label Use; Oligoribonucleotides, Antisense; Piperidines; Precision Medicine; Pyrazines; Pyridines; Riluzole; RNAi Therapeutics; Stem Cell Transplantation; Superoxide Dismutase; Thiazoles; United States; United States Food and Drug Administration | 2017 |
Evidence for mast cells contributing to neuromuscular pathology in an inherited model of ALS.
Topics: Amyotrophic Lateral Sclerosis; Animals; Axons; Benzamides; Disease Models, Animal; Male; Mast Cells; Muscle, Skeletal; Neuromuscular Diseases; Neuromuscular Junction; Piperidines; Pyridines; Rats; Thiazoles | 2017 |
Dual protein kinase and nucleoside kinase modulators for rationally designed polypharmacology.
Topics: A549 Cells; Antineoplastic Agents; Benzamides; Cell Line, Tumor; Crystallography, X-Ray; Deoxycytidine; Deoxycytidine Kinase; Drug Design; Drug Resistance, Neoplasm; Enzyme Activation; Gemcitabine; Humans; Imatinib Mesylate; Models, Biological; Models, Molecular; Phosphorylation; Piperidines; Polypharmacology; Protein Kinase Inhibitors; Proteomics; Pyridines; Thiazoles | 2017 |
Motor neuron disease in 2017: Progress towards therapy in motor neuron disease.
Topics: Amyotrophic Lateral Sclerosis; Benzamides; Edaravone; Humans; Muscular Atrophy, Spinal; Neuroprotective Agents; Oligonucleotides; Oligoribonucleotides, Antisense; Piperidines; Pyridines; Thiazoles; Thionucleotides | 2018 |
Decrease of cocaine, but not heroin, self-administration and relapse by the tyrosine kinase inhibitor masitinib in male Sprague Dawley rats.
Topics: Administration, Oral; Analgesics, Opioid; Animals; Behavior, Addictive; Benzamides; Cocaine; Conditioning, Operant; Dopamine Uptake Inhibitors; Heroin; Male; Motivation; Piperidines; Protein Kinase Inhibitors; Pyridines; Rats; Rats, Sprague-Dawley; Recurrence; Reinforcement, Psychology; Self Administration; Thiazoles | 2018 |
Masitinib in treatment of pancreatic cancer.
Topics: Benzamides; Humans; Pancreatic Neoplasms; Piperidines; Protein Kinase Inhibitors; Pyridines; Survival Rate; Thiazoles | 2018 |
Cyclooxygenase inhibitors potentiate receptor tyrosine kinase therapies in bladder cancer cells in vitro.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Axitinib; Benzamides; Caspases; Cell Line, Tumor; Cell Survival; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Dinoprostone; Dogs; Dose-Response Relationship, Drug; Drug Synergism; Humans; Imidazoles; Indazoles; Indomethacin; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-kit; Pyridines; Receptors, Platelet-Derived Growth Factor; Signal Transduction; Thiazoles; Urinary Bladder Neoplasms | 2018 |
In Vitro Screening of Six Protein Kinase Inhibitors for Time-Dependent Inhibition of CYP2C8 and CYP3A4: Possible Implications with regard to Drug-Drug Interactions.
Topics: Benzamides; Benzimidazoles; Cytochrome P-450 CYP2C8; Cytochrome P-450 CYP2C8 Inhibitors; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Humans; Indoles; Inhibitory Concentration 50; Microsomes, Liver; Phthalazines; Piperidines; Pyridines; Pyridones; Pyrimidinones; Quinolones; Staurosporine; Thiazoles | 2018 |
Identification and characterization of prescription drugs that change levels of 7-dehydrocholesterol and desmosterol.
Topics: Benzamides; Cell Line, Tumor; Dehydrocholesterols; Desmosterol; Drug Evaluation, Preclinical; Gene Expression Regulation; High-Throughput Screening Assays; Humans; Imidazoles; Nerve Tissue Proteins; Oxidoreductases Acting on CH-CH Group Donors; Piperidines; Prescription Drugs; Pyridazines; Pyridines; Thiazoles; United States; United States Food and Drug Administration | 2018 |
Mast cells and neutrophils mediate peripheral motor pathway degeneration in ALS.
Topics: Amyotrophic Lateral Sclerosis; Animals; Axons; Benzamides; Cell Degranulation; Disease Models, Animal; Humans; Male; Mast Cells; Motor Neurons; Muscle, Skeletal; Neuromuscular Junction; Neutrophil Infiltration; Neutrophils; Piperidines; Protein Kinase Inhibitors; Pyridines; Rats; Rats, Transgenic; Superoxide Dismutase; Superoxide Dismutase-1; Thiazoles; Treatment Outcome | 2018 |
In pursuit of the normal progressor: the holy grail for ALS clinical trial design?
Topics: Amyotrophic Lateral Sclerosis; Benzamides; Clinical Trials as Topic; Humans; Piperidines; Pyridines; Riluzole; Thiazoles | 2020 |
Prospective clinical trial of masitinib mesylate treatment for advanced stage III and IV canine malignant melanoma.
Topics: Animals; Benzamides; Dog Diseases; Dogs; Melanoma; Piperidines; Prospective Studies; Pyridines; Skin Neoplasms; Thiazoles | 2020 |
Extensive vitiligo associated to response to c-kit inhibitor in metastatic mucosal melanoma.
Topics: Antineoplastic Agents; Benzamides; Female; Humans; Lymphatic Metastasis; Melanoma; Middle Aged; Piperidines; Prognosis; Proto-Oncogene Proteins c-kit; Pyridines; Thiazoles; Vitiligo; Vulvar Neoplasms | 2020 |
The secondary KIT mutation p.Ala510Val in a cutaneous mast cell tumour carrying the activating mutation p.Asn508Ile confers resistance to masitinib in dogs.
Topics: Animals; Antineoplastic Agents; Benzamides; Dog Diseases; Dogs; Drug Resistance, Neoplasm; Female; Gain of Function Mutation; HEK293 Cells; Humans; Mastocytosis, Cutaneous; Piperidines; Proto-Oncogene Proteins c-kit; Pyridines; Skin Neoplasms; Thiazoles; Vinblastine | 2020 |
Effects of Chronic Masitinib Treatment in APPswe/PSEN1dE9 Transgenic Mice Modeling Alzheimer's Disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Animals; Benzamides; Cognition; Disease Models, Animal; Male; Mice, Transgenic; Piperidines; Presenilin-1; Pyridines; Synapses; Thiazoles | 2020 |
Overview of current and emerging therapies for amytrophic lateral sclerosis.
Topics: Amyotrophic Lateral Sclerosis; Antibodies, Monoclonal, Humanized; Benzamides; Edaravone; Humans; Mesenchymal Stem Cells; Oligonucleotides; Piperidines; Pyridines; Riluzole; Thiazoles | 2020 |
UV spectrophotometric methods for quantitative determination of masitinib; extraction of qualitative information.
Topics: Benzamides; Humans; Piperidines; Pyridines; Spectrophotometry; Spectrophotometry, Ultraviolet; Tablets; Thiazoles | 2021 |
Development and progression of proteinuria in dogs treated with masitinib for neoplasia: 28 cases (2010-2019).
Topics: Animals; Benzamides; Creatinine; Dog Diseases; Dogs; Neoplasms; Piperidines; Proteinuria; Pyridines; Thiazoles | 2021 |
In Silico Characterization of Masitinib Interaction with SARS-CoV-2 Main Protease.
Topics: Benzamides; Catalytic Domain; Coronavirus 3C Proteases; Cysteine Proteinase Inhibitors; Hydrogen Bonding; Molecular Dynamics Simulation; Mutation; Piperidines; Protein Binding; Pyridines; SARS-CoV-2; Static Electricity; Thiazoles | 2021 |
Masitinib is a broad coronavirus 3CL inhibitor that blocks replication of SARS-CoV-2.
Topics: A549 Cells; Animals; Antiviral Agents; Benzamides; Catalytic Domain; Coronavirus 3C Proteases; Coronavirus OC43, Human; COVID-19; COVID-19 Drug Treatment; Cysteine Proteinase Inhibitors; HEK293 Cells; Humans; Inhibitory Concentration 50; Mice; Mice, Transgenic; Microbial Sensitivity Tests; Piperidines; Pyridines; SARS-CoV-2; Thiazoles; Viral Load; Virus Replication | 2021 |
The pathogenic role of c-Kit+ mast cells in the spinal motor neuron-vascular niche in ALS.
Topics: Aged; Aged, 80 and over; Amyotrophic Lateral Sclerosis; Animals; Astrocytes; Benzamides; Case-Control Studies; Chymases; Cyclooxygenase 2; Female; Humans; Male; Mast Cells; Mice; Microvessels; Middle Aged; Motor Neurons; Neuroinflammatory Diseases; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyridines; Spinal Cord; Stem Cell Factor; Thiazoles; Tryptases | 2021 |
Additive cell protective and oxidative stress reducing effects of combined treatment with cromolyn sodium and masitinib on MPTP-induced toxicity in SH-SY5Y neuroblastoma cells.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Benzamides; Cell Line, Tumor; Cromolyn Sodium; Cytoprotection; Humans; Oxidative Stress; Piperidines; Pyridines; Thiazoles | 2022 |
Evaluation of the therapeutic potential of masitinib and expression of its specific targets c-Kit, PDGFR-α, PDGFR-β, and Lyn in canine prostate cancer cell lines.
Topics: Adenocarcinoma; Animals; Benzamides; Carcinoma, Transitional Cell; Cell Line; Dog Diseases; Dogs; Male; Piperidines; Prostatic Neoplasms; Proto-Oncogene Proteins c-kit; Pyridines; Receptor, Platelet-Derived Growth Factor alpha; Receptor, Platelet-Derived Growth Factor beta; Thiazoles | 2022 |
c-kit inhibitor masitinib induces reactive oxygen species-dependent apoptosis in c-kit-negative HepG2 cells.
Topics: Animals; Apoptosis; Benzamides; Cell Line, Tumor; Dogs; Hep G2 Cells; Humans; JNK Mitogen-Activated Protein Kinases; Piperidines; Proto-Oncogene Proteins c-kit; Pyridines; Reactive Oxygen Species; Thiazoles | 2022 |
Cytochromes P450 2C8 and 3A Catalyze the Metabolic Activation of the Tyrosine Kinase Inhibitor Masitinib.
Topics: Activation, Metabolic; Benzamides; Catalysis; COVID-19; Cytochrome P-450 Enzyme System; Humans; Microsomes, Liver; NADP; Piperidines; Potassium Cyanide; Protein Kinase Inhibitors; Pyridines; Thiazoles | 2022 |
Interaction of Masitinib with Organic Cation Transporters.
Topics: Animals; COVID-19; Humans; Mice; Organic Cation Transport Proteins; Organic Cation Transporter 2; Thiazoles | 2022 |
MasitinibL shows promise as a drug-like analog of masitinib that elicits comparable SARS-Cov-2 3CLpro inhibition with low kinase preference.
Topics: Antiviral Agents; COVID-19; Humans; SARS-CoV-2; Thiazoles | 2023 |